Positive News SentimentPositive NewsNASDAQ:PASG Passage Bio (PASG) Stock Price, News & Analysis $7.14 +0.10 (+1.42%) As of 10:19 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Passage Bio Stock (NASDAQ:PASG) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Passage Bio alerts:Sign Up Key Stats Today's Range$7.01▼$7.0150-Day Range$5.27▼$9.2252-Week Range$5.12▼$26.60Volume181 shsAverage Volume27,950 shsMarket Capitalization$22.71 millionP/E RatioN/ADividend YieldN/APrice Target$91.75Consensus RatingBuy Company Overview Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania. Read More Passage Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks82nd Percentile Overall ScorePASG MarketRank™: Passage Bio scored higher than 82% of companies evaluated by MarketBeat, and ranked 213th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingPassage Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePassage Bio has only been the subject of 3 research reports in the past 90 days.Read more about Passage Bio's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Passage Bio are expected to grow in the coming year, from ($1.03) to ($0.74) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Passage Bio is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Passage Bio is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPassage Bio has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Passage Bio's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.21% of the float of Passage Bio has been sold short.Short Interest Ratio / Days to CoverPassage Bio has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Passage Bio has recently decreased by 15.79%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPassage Bio does not currently pay a dividend.Dividend GrowthPassage Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.21% of the float of Passage Bio has been sold short.Short Interest Ratio / Days to CoverPassage Bio has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Passage Bio has recently decreased by 15.79%, indicating that investor sentiment is improving significantly. News and Social Media4.4 / 5News Sentiment1.88 News SentimentPassage Bio has a news sentiment score of 1.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Passage Bio this week, compared to 1 article on an average week.Search Interest6 people have searched for PASG on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.MarketBeat Follows4 people have added Passage Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Passage Bio insiders have bought 271.98% more of their company's stock than they have sold. Specifically, they have bought $733,658.00 in company stock and sold $197,233.00 in company stock.Percentage Held by InsidersOnly 5.00% of the stock of Passage Bio is held by insiders.Percentage Held by Institutions53.48% of the stock of Passage Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Passage Bio's insider trading history. Receive PASG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Passage Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PASG Stock News HeadlinesPassage Bio to Participate in H.C. Wainwright 27th Annual Global Investment Conference4 hours ago | globenewswire.comPassage Bio (PASG) Receives a Buy from TD CowenAugust 15, 2025 | theglobeandmail.com“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.August 28 at 2:00 AM | Weiss Ratings (Ad)Passage Bio price target lowered to $67 from $260 at CanaccordAugust 14, 2025 | msn.comPassage Bio Reports Q2 2025 Progress and FinancialsAugust 13, 2025 | msn.comPassage Bio reports Q2 EPS ($2.96) vs ($5.09) last yearAugust 12, 2025 | msn.comPassage Bio Reports Promising Q2 2025 Financial ResultsAugust 12, 2025 | msn.comPassage Bio Reports Second Quarter 2025 Financial Results and Provides Recent Business HighlightsAugust 12, 2025 | globenewswire.comSee More Headlines PASG Stock Analysis - Frequently Asked Questions How have PASG shares performed this year? Passage Bio's stock was trading at $11.3420 at the beginning of the year. Since then, PASG stock has decreased by 37.0% and is now trading at $7.14. How were Passage Bio's earnings last quarter? Passage Bio, Inc. (NASDAQ:PASG) released its quarterly earnings results on Tuesday, August, 12th. The company reported ($2.96) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.00) by $1.04. When did Passage Bio's stock split? Shares of Passage Bio reverse split on Monday, July 14th 2025.The 1-20 reverse split was announced on Thursday, July 10th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 11th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Passage Bio IPO? Passage Bio (PASG) raised $126 million in an IPO on Friday, February 28th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Chardan was co-manager. Who are Passage Bio's major shareholders? Passage Bio's top institutional investors include Orbimed Advisors LLC (194.08%), Geode Capital Management LLC (17.26%), Bridgeway Capital Management LLC (13.08%) and Simplex Trading LLC. Insiders that own company stock include Lynx1 Capital Management Lp, Orbimed Advisors Llc, Mark S Forman, Alexandros Fotopoulos, Kathleen Borthwick and Simona King. View institutional ownership trends. How do I buy shares of Passage Bio? Shares of PASG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Passage Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Passage Bio investors own include Enovix (ENVX), Ginkgo Bioworks (DNA), COMPASS Pathways (CMPS), Rambus (RMBS), Toast (TOST), Globant (GLOB) and Luminar Technologies (LAZR). Company Calendar Last Earnings8/12/2025Today8/28/2025Next Earnings (Estimated)11/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PASG CIK1787297 Webwww.passagebio.com Phone267-866-0311FaxN/AEmployees130Year FoundedN/APrice Target and Rating Average Price Target for Passage Bio$91.75 High Price Target$140.00 Low Price Target$40.00 Potential Upside/Downside+1,203.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($18.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$64.77 million Net MarginsN/A Pretax MarginN/A Return on Equity-103.87% Return on Assets-59.95% Debt Debt-to-Equity RatioN/A Current Ratio3.05 Quick Ratio3.05 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$12.04 per share Price / Book0.58Miscellaneous Outstanding Shares3,180,000Free Float3,020,000Market Cap$22.39 million OptionableOptionable Beta1.81 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:PASG) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Passage Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Passage Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.